Splash Beverage Group, Inc. entered into an addendum to its exclusive global license agreement for CannEpil with Argent BioPharma Limited on July 28, 2026. The amendment expands the field of use to include veterinary applications and establishes a tiered royalty structure: 10% of net revenue from veterinary sales and 15% from human applications. Splash intends to initially evaluate CannEpil for companion-animal oncology and chronic pain management, pursuing FDA Center for Veterinary Medicine approval. The company is finalizing a strategic joint venture with an established cannabinoid pharmaceutical firm to lead this development program. Splash Beverage Group, Inc. operates in the cannabinoid health, wellness, and biopharmaceutical sector.
